Comparison of the efficacy of prednisolone, montelukast, and omalizumab in an experimental allergic rhinitis model

Basit Öğe Kaydı
dc.contributor.authorBozkurt, Mete Kaan
dc.contributor.authorTülek, Baykal
dc.contributor.authorBozkurt, Banu
dc.contributor.authorAkyürek, Nalan
dc.contributor.authorÖz, Mehmet
dc.contributor.authorKıyıcı, Aysel
dc.date.accessioned2020-03-26T18:49:50Z
dc.date.available2020-03-26T18:49:50Z
dc.date.issued2014
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractAim: To compare the efficacy of prednisolone, montelukast, and omalizumab in reducing allergic symptoms and inflammation at tissue level in an experimental allergic rhinitis model. Materials and methods: Forty Sprague Dawley rats were randomized into 5 groups as naive (NS/NC), sensitized/challenged (S/C) by subcutaneous ovalbumin antigen injection, and montelukast-, prednisolone-, and omalizumab- treated groups. A nasal allergen challenge was performed every day from day 20 to day 26. The number of sneezes and nasal/eye rubbing movements, IL-4 and CysLT levels in serum, nasal and bronchoalveolar lavage fluids determined by ELISA, and histopathological findings of nasal mucosa, sinus, and lung tissues were compared. Results: All of the treatments significantly controlled the allergic symptoms of sneezing and nasal/eye rubbing (P < 0.05). IL-4 and CysLT levels on days 20 and 26 were significantly higher in the S/C group compared to the NS/NC group (P < 0.05). Montelukast significantly decreased serum and nasal IL-4 and CysLT levels (P < 0.05), prednisolone decreased nasal lavage IL-4 and CysLT levels (P < 0.05), and omalizumab lowered nasal lavage CysLT levels (P < 0.05). Conclusion: Prednisolone, montelukast, and omalizumab were found to be effective in controlling the allergic symptoms of allergic rhinitis and upper/lower airway inflammation in an experimental allergic rhinitis model.en_US
dc.description.sponsorshipTUBITAKTurkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK) [SBAG-108S402]en_US
dc.description.sponsorshipThis project was supported by a grant from TUBITAK (SBAG-108S402).en_US
dc.identifier.doi10.3906/sag-1212-23en_US
dc.identifier.endpage447en_US
dc.identifier.issn1300-0144en_US
dc.identifier.issn1303-6165en_US
dc.identifier.issue3en_US
dc.identifier.pmid25558647en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage439en_US
dc.identifier.urihttps://dx.doi.org/10.3906/sag-1212-23
dc.identifier.urihttps://hdl.handle.net/20.500.12395/30696
dc.identifier.volume44en_US
dc.identifier.wosWOS:000334063700016en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTUBITAK SCIENTIFIC & TECHNICAL RESEARCH COUNCIL TURKEYen_US
dc.relation.ispartofTURKISH JOURNAL OF MEDICAL SCIENCESen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectExperimental allergic rhinitisen_US
dc.subjectairway inflammationen_US
dc.subjectprednisoloneen_US
dc.subjectmontelukasten_US
dc.subjectomalizumaben_US
dc.subjectimmunoglobulin Een_US
dc.subjectcysteinyl leukotrieneen_US
dc.subjectinterleukin-4en_US
dc.titleComparison of the efficacy of prednisolone, montelukast, and omalizumab in an experimental allergic rhinitis modelen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu